1. In Vivo
  2. >>Global Vision

Reinventing Prevention: Milken Institute Foresees Another Route Using Private And Public Funding

Pension Funds Part Of Radical Funding Plan To ‘Pivot To Prevention’

 
• By Ashley Yeo

New funding mechanisms are required to give more momentum to prevention in the community and thereby relieve pressure on overburdened health care providers like the UK National Health Service. So says Simon Radford, a director at global thinktank the Milken Institute, which sees a solution in more funding for community-level prevention.

(Shutterstock)
Key Takeaways
  • The Milken Institute proposes a Prevention Fund to support community-level preventive health initiatives in the UK, aiming to reduce the burden on the NHS by financing Community Health Hubs for preventive care services.
  • The fund will use a three-pronged approach: a blended finance fund combining public, philanthropic, and private capital; a business relief fund with tax advantages for high net-worth individuals; and a social impact bond to attract further investment.
  • The report's recommendations are intended to be part of the UK's NHS 10 Year Health Plan, aiming to make preventive health measures a permanent feature of the healthcare system, with a focus on innovative finance solutions and pension fund investments.

Against the backdrop of ever-rising demand on national health care providers, the Milken Institute global thinktank is proposing a Prevention Fund, which would function as support system for the overstretched...

The initiative is part of Milken’s long-term global “Project Prevent,” launched in May 2024 to “galvanize momentum around this agenda across all the geographies where Milken works.” So said Esther...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Unpacking The Impact Of Trump’s Tariffs On Drug Pricing And Production

 
• By Ed Silverman

Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.

Barcelona’s S2 Xpeed Accelerates Hardware-Based Medtech Start-Ups From Prototype To Market

 
• By Marion Webb

S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity.

Rising Leaders 2025: Partnerships Propel Crystal Qin’s LaNova To Record-Breaking Merck Deal

 
• By Brian Yang

Crystal Qin has led LaNova Medicines’ swift rise in the biotech world through strategic partnerships and innovative R&D, highlighted by a record deal with big pharma.

More from In Vivo

How Vir Bio CEO Marianne De Backer Is Rebuilding Commercial Momentum

 
• By David Wild

From billion-dollar COVID antibody to a strategic reset, Marianne De Backer is navigating Vir's comeback through pipeline focus and disciplined leadership.

Execs On The Move: April 2025

 
• By In Vivo Team

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

AI In Drug Discovery: The Patent Implications

 
• By David Wild

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.